PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15100096-5 2004 Luminally perfusing with either enalaprilat (10(-4) M) to inhibit production of angiotensin II or losartan (10(-8) M) to block the angiotensin receptor decreased the proximal tubule volume reabsorptive rate in DHT-treated rats to a significantly greater degree than in control vehicle-injected rats. Enalaprilat 32-43 angiotensinogen Rattus norvegicus 80-94 2438497-16 1986 With MK422 i.v.t., there was a decrease in brain ANG II. Enalaprilat 5-10 angiotensinogen Rattus norvegicus 49-55 2989171-9 1985 Plasma angiotensin II levels were increased by the vasopressin antagonist and decreased by enalaprilat. Enalaprilat 91-102 angiotensinogen Rattus norvegicus 7-21 22395404-5 2012 It could be concluded that enalaprilat can inhibit the cardiac fibroblast proliferation induced by Ang II via blocking ROS/P38MAPK/TGF-beta(1) signaling pathways and the study provides a theoretical proof for the application of ACEIs in treating myocardial fibrosis and discovering the primary mechanism through which ACEIs inhibit CFb proliferation. Enalaprilat 27-38 angiotensinogen Rattus norvegicus 99-105 24342267-0 2014 Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines. Enalaprilat 20-31 angiotensinogen Rattus norvegicus 85-99 16650303-8 2006 CONCLUSION: We have concluded that enalaprilat interferes in this alteration of permeability, suggesting that angiotensin II is involved in the loss of selectivity of the glomerular membrane. Enalaprilat 35-46 angiotensinogen Rattus norvegicus 110-124 15992826-10 2005 Concurrent treatment with Enalaprilat reversed the hypertension induced by ANG II infusion (98 +/- 3 versus 155 +/- 4 mmHg; P < 0.001). Enalaprilat 26-37 angiotensinogen Rattus norvegicus 75-81 15992826-12 2005 Enalaprilat significantly decreased renal ACE activity in ANG II-treated rats, compared to ANG II alone (11.4 +/- 1.0 versus 59.2 +/- 11.9 units/mg protein; P < 0.001). Enalaprilat 0-11 angiotensinogen Rattus norvegicus 58-64 15992826-13 2005 Intrarenal ANG II was increased in ANG II-infused rats, compared to control animals (52.9 +/- 7.1 versus 23.0 +/- 3.2 fmol/mg tissue; P < 0.001), and Enalaprilat prevented ANG II-induced increases in intrarenal ANG II (29.9 +/- 2.6 versus 52.9 +/- 7.1 fmol/mg tissue; P < 0.05). Enalaprilat 153-164 angiotensinogen Rattus norvegicus 11-17 15992826-13 2005 Intrarenal ANG II was increased in ANG II-infused rats, compared to control animals (52.9 +/- 7.1 versus 23.0 +/- 3.2 fmol/mg tissue; P < 0.001), and Enalaprilat prevented ANG II-induced increases in intrarenal ANG II (29.9 +/- 2.6 versus 52.9 +/- 7.1 fmol/mg tissue; P < 0.05). Enalaprilat 153-164 angiotensinogen Rattus norvegicus 35-41 15992826-13 2005 Intrarenal ANG II was increased in ANG II-infused rats, compared to control animals (52.9 +/- 7.1 versus 23.0 +/- 3.2 fmol/mg tissue; P < 0.001), and Enalaprilat prevented ANG II-induced increases in intrarenal ANG II (29.9 +/- 2.6 versus 52.9 +/- 7.1 fmol/mg tissue; P < 0.05). Enalaprilat 153-164 angiotensinogen Rattus norvegicus 35-41 15992826-13 2005 Intrarenal ANG II was increased in ANG II-infused rats, compared to control animals (52.9 +/- 7.1 versus 23.0 +/- 3.2 fmol/mg tissue; P < 0.001), and Enalaprilat prevented ANG II-induced increases in intrarenal ANG II (29.9 +/- 2.6 versus 52.9 +/- 7.1 fmol/mg tissue; P < 0.05). Enalaprilat 153-164 angiotensinogen Rattus norvegicus 35-41 12191964-1 2002 It was recently demonstrated that angiotensin II (AngII) concentrations in the renal interstitial fluid (RIF) of anesthetized rats were in the nanomolar range and were not reduced by intra-arterial infusion of an angiotensin-converting enzyme (ACE) inhibitor (enalaprilat). Enalaprilat 260-271 angiotensinogen Rattus norvegicus 34-48 12191964-1 2002 It was recently demonstrated that angiotensin II (AngII) concentrations in the renal interstitial fluid (RIF) of anesthetized rats were in the nanomolar range and were not reduced by intra-arterial infusion of an angiotensin-converting enzyme (ACE) inhibitor (enalaprilat). Enalaprilat 260-271 angiotensinogen Rattus norvegicus 50-55 12191964-11 2002 These results indicate that addition of AngI in the interstitial compartment leads to low but significant conversion to AngII via ACE activity (blocked by enalaprilat). Enalaprilat 155-166 angiotensinogen Rattus norvegicus 120-125 12191964-3 2002 Studies were also performed to determine the effects of enalaprilat on the de novo formation of RIF AngII elicited by interstitial infusion of AngI. Enalaprilat 56-67 angiotensinogen Rattus norvegicus 100-105 10444586-13 1999 Likewise, intermicrovillar cleft and endosomal ANG II levels decreased by 61% and 52%, respectively, in enalaprilat-treated animals. Enalaprilat 104-115 angiotensinogen Rattus norvegicus 47-53 9673422-0 1998 Effect of angiotensin II receptor blockade on the interaction between enalaprilat and doxazosin in rat tail arteries. Enalaprilat 70-81 angiotensinogen Rattus norvegicus 10-24 10498289-10 1999 These data show that the ACE inhibitors moexiprilat and enalaprilat inhibit Ang II induced proliferation of cardiac fibroblasts according to their relative potency of ACE inhibition in vitro. Enalaprilat 56-67 angiotensinogen Rattus norvegicus 76-82 9887083-2 1999 Eight to ten weeks after inducing HF in rats by coronary artery ligation, we administered enalaprilat to suppress ANG II synthesis and studied renal arteriolar function using the in vitro blood-perfused juxtamedullary nephron technique. Enalaprilat 90-101 angiotensinogen Rattus norvegicus 114-120 9673422-2 1998 Previous work has shown that enalaprilat, an inhibitor of angiotensin-converting enzyme (ACE), potentiated the actions of alpha 1-adrenoceptor antagonists; it was hypothesized that angiotensin II (AngII) modulated the activity of alpha 1-adrenoceptors. Enalaprilat 29-40 angiotensinogen Rattus norvegicus 181-195 9673422-2 1998 Previous work has shown that enalaprilat, an inhibitor of angiotensin-converting enzyme (ACE), potentiated the actions of alpha 1-adrenoceptor antagonists; it was hypothesized that angiotensin II (AngII) modulated the activity of alpha 1-adrenoceptors. Enalaprilat 29-40 angiotensinogen Rattus norvegicus 197-202 9062366-5 1997 After acute blockade of ANG II formation by iv enalaprilat injection in sodium-restricted animals, ANG II produced a 40% decrease in renal blood flow, a level between untreated dietary groups and less than high salt diet. Enalaprilat 47-58 angiotensinogen Rattus norvegicus 24-30 9321871-10 1997 However, in enalaprilate-pretreated animals, the inhibition of alkaline secretion due to splanchnic nerve stimulation was transient, a response that became sustained on angiotensin II substitution. Enalaprilat 12-24 angiotensinogen Rattus norvegicus 169-183 9422816-15 1997 These results are more consistent with the antihypertensive effects of enalaprilat or MDL 100,240 in transgenic ((mRen-2)27) rats being due to suppression of angiotensin II production, than due to inhibition of bradykinin degradation. Enalaprilat 71-82 angiotensinogen Rattus norvegicus 158-172 9062366-5 1997 After acute blockade of ANG II formation by iv enalaprilat injection in sodium-restricted animals, ANG II produced a 40% decrease in renal blood flow, a level between untreated dietary groups and less than high salt diet. Enalaprilat 47-58 angiotensinogen Rattus norvegicus 99-105 8675701-7 1996 When 10(-11) or 10(-8) M exogenous angiotensin II was added to enalaprilat (10(-4) M) in the luminal perfusate, fluid reabsorption returned to its baseline rate (Jv = 2.78 +/- 0.35 nl/mm.min). Enalaprilat 63-74 angiotensinogen Rattus norvegicus 35-49 8834708-12 1996 These results also confirm that sympathetic nerve terminal blockade by losartan or the blockade of endogenous angiotensin II formation by enalaprilat are likely to participate in the antihypertensive action of AT1 angiotensin II receptor antagonists and angiotensin converting enzyme. Enalaprilat 138-149 angiotensinogen Rattus norvegicus 110-124 8834708-12 1996 These results also confirm that sympathetic nerve terminal blockade by losartan or the blockade of endogenous angiotensin II formation by enalaprilat are likely to participate in the antihypertensive action of AT1 angiotensin II receptor antagonists and angiotensin converting enzyme. Enalaprilat 138-149 angiotensinogen Rattus norvegicus 214-228 8179016-5 1994 Captopril and enalaprilat, ANG II-converting enzyme inhibitors, decreased the pressor response to ANG I while increasing the pressor response to ANG II and III. Enalaprilat 14-25 angiotensinogen Rattus norvegicus 27-33 7477443-0 1995 Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Enalaprilat 16-27 angiotensinogen Rattus norvegicus 108-122 7882177-7 1994 Because resetting is angiotensin II dependent, the converting enzyme inhibitor Enalaprilat was used to provide angiotensin II blockade. Enalaprilat 79-90 angiotensinogen Rattus norvegicus 21-35 7882177-7 1994 Because resetting is angiotensin II dependent, the converting enzyme inhibitor Enalaprilat was used to provide angiotensin II blockade. Enalaprilat 79-90 angiotensinogen Rattus norvegicus 111-125 7503796-7 1995 When 125I-Ang I was perfused in the presence of ACE inhibitors (enalaprilat, ramiprilat) in concentrations up to 130 microM, the formation of Ang II was only partially inhibited (approximately 50%). Enalaprilat 64-75 angiotensinogen Rattus norvegicus 142-148 8575109-2 1995 Experiments were designed to evaluate the hypothesis that cyclo-oxygenase products modulate the influence of angiotensin II (AII) on the renal juxtamedullary microvasculature of enalaprilat-treated rats. Enalaprilat 178-189 angiotensinogen Rattus norvegicus 109-123 8575109-2 1995 Experiments were designed to evaluate the hypothesis that cyclo-oxygenase products modulate the influence of angiotensin II (AII) on the renal juxtamedullary microvasculature of enalaprilat-treated rats. Enalaprilat 178-189 angiotensinogen Rattus norvegicus 125-128 7522595-2 1994 Preincubation with captopril, enalaprilat, enalapril, or ramiprilat for 40 min significantly reduced the angiotensin II-induced transplasma membrane calcium influx but did not influence the angiotension II-induced calcium release from internal stores. Enalaprilat 30-41 angiotensinogen Rattus norvegicus 105-119 8179016-5 1994 Captopril and enalaprilat, ANG II-converting enzyme inhibitors, decreased the pressor response to ANG I while increasing the pressor response to ANG II and III. Enalaprilat 14-25 angiotensinogen Rattus norvegicus 145-151 8282342-2 1994 Enalaprilat (2 mg IV) was administered to anesthetized rats to reduce endogenous Ang II levels. Enalaprilat 0-11 angiotensinogen Rattus norvegicus 81-87 1646895-12 1991 The small but significant inhibition found with Enalaprilat for the larger arterioles suggests that the local angiotensin II level may affect the response to cocaine. Enalaprilat 48-59 angiotensinogen Rattus norvegicus 110-124 8244513-7 1993 Enalaprilat similarly decreased the Ang II-induced contraction. Enalaprilat 0-11 angiotensinogen Rattus norvegicus 36-42 8384414-12 1993 Blockade of ANG II by enalaprilat or by the AT1-receptor blocker losartan potassium significantly inhibited regulatory vasodilatation and vasoconstriction at low RPP. Enalaprilat 22-33 angiotensinogen Rattus norvegicus 12-18 1328628-7 1992 Enalaprilat inhibited in a dose-dependent manner the increases in stromal cell alkaline phosphatase activity and media PGE concentration that occurred in the control cultures; these effects were fully reversed by concurrent treatment with angiotensin II. Enalaprilat 0-11 angiotensinogen Rattus norvegicus 239-253 1328628-8 1992 The inhibition of stromal alkaline phosphatase activity was also reversed by PGE2; conversely, the ability of angiotensin II to reverse the effect of enalaprilat was lost in the presence of indomethacin. Enalaprilat 150-161 angiotensinogen Rattus norvegicus 110-124 1317352-4 1992 Pretreatment with the angiotensin converting enzyme inhibitor enalaprilat (2 mg/kg) eliminated angiotensin II formation and augmented circulating levels of angiotensin I and angiotensin-(1-7) in spontaneously hypertensive and Wistar-Kyoto rats. Enalaprilat 62-73 angiotensinogen Rattus norvegicus 95-109 1967591-7 1990 The addition of angiotensin II after enalaprilic acid (10(-4) M) did not normalize the response in +T and -T. Enalaprilic acid diminishes the contractile response of the papillary muscle to beta-adrenergic stimulation. Enalaprilat 110-126 angiotensinogen Rattus norvegicus 16-30